Synergistic targeting of TrxR1 and ATM/AKT pathway in human colon cancer cells - 27/04/24
Abstract |
Thioredoxin reductase 1 (TrxR1) has emerged as a promising target for cancer therapy. In our previous research, we discovered several new TrxR1 inhibitors and found that they all have excellent anti-tumor activity. At the same time, we found these TrxR1 inhibitors all lead to an increase in AKT phosphorylation in cancer cells, but the detailed role of AKT phosphorylation in TrxR1 inhibitor-mediated cell death remains unclear. In this study, we identified the combination of AKT and TrxR1 inhibitor displayed a strong synergistic effect in colon cancer cells. Furthermore, we demonstrated that the synergistic effect of auranofin (TrxR1 inhibitor) and MK-2206 (AKT inhibitor) was caused by ROS accumulation. Importantly, we found that ATM inhibitor KU-55933 can block the increase of AKT phosphorylation caused by auranofin, and exhibited a synergistic effect with auranofin. Taken together, our study demonstrated that the activation of ATM/AKT pathway is a compensatory mechanism to cope with ROS accumulation induced by TrxR1 inhibitor, and synergistic targeting of TrxR1 and ATM/AKT pathway is a promising strategy for treating colon cancer.
Le texte complet de cet article est disponible en PDF.Highlights |
• | The AKT phosphorylation level in colon cancer cells was significantly increased after TrxR1 inhibitors treatment. |
• | ROS mediates the synergism of TrxR1 and ATM/AKT pathway inhibitors. |
• | TrxR1 and ATM/AKT pathway inhibitors can synergistically upregulate the autophagy level in colon cancer cells. |
• | Synergistic targeting of TrxR1 and ATM/AKT pathway is a promising strategy for treating colon cancer. |
Abbreviations : AF, MK, KU, PL, TrxR1, AKT, ATM, ER, ROS, NAC, DCFH-DA, SP, JNK, 3-MA
Keywords : TrxR1, AKT, ROS, Autophagy, Colon cancer
Plan
Vol 174
Article 116507- mai 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?